- Patent Title: Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
-
Application No.: US16093426Application Date: 2017-04-17
-
Publication No.: US11141413B2Publication Date: 2021-10-12
- Inventor: Dana T. Aftab , Gisela Schwab , Colin Hessel , Christian Scheffold , Steven Lacy , Dale Miles , Alan Arroyo , Mark Dean
- Applicant: Exelixis, Inc.
- Applicant Address: US CA Alameda
- Assignee: Exelixis, Inc.
- Current Assignee: Exelixis, Inc.
- Current Assignee Address: US CA Alameda
- Agency: Honigman LLP
- Agent Heidi M. Berven
- International Application: PCT/US2017/027965 WO 20170417
- International Announcement: WO2017/181187 WO 20171019
- Main IPC: A61K31/47
- IPC: A61K31/47 ; A61K31/16 ; A61P35/00 ; A61K9/20 ; A61K9/28
Abstract:
The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
Public/Granted literature
Information query
